Renal Cell Carcinoma (RCC) is the most common kidney cancer that arises from the renal tubules, accounting for around 85% of all malignant kidney cancers. Every year, about 60,000 new instances of RCC are reported, with approximately 14,000 people dying from the disease. In the United States and other countries, the frequency of this has been steadily growing. A better understanding of RCC's molecular biology and genetics has revealed multiple signalling pathways implicated in the cancer's growth. Agents licenced by the Food and Drug Administration (FDA) that target these pathways have been reported to make significant advancements in the treatment of RCC. Because of their therapeutic value and enhanced survival in patients with metastatic disease, these medications have become the treatments of choice. Patients, on the other hand, eventually relapse and acquire resistance to these medications. The search for more effective medicines and preventative methods is necessary to enhance outcomes and find approaches for establishing long-term sustainable remission. One of these techniques to lessen the incidence of RCC is to treat it with natural products. Recent research has focused on these chemoprevention medicines as anti-cancer therapeutics due to their ability to limit tumour cell growth while avoiding the significant side effects associated with synthetic chemicals. The present state of knowledge on natural products and their mechanisms of action as anti-cancer medicines is discussed in this study. The information included in this study will be useful in determining whether these products can be used alone or in combination with chemotherapy to prevent and cure RCC.
